25 Jun 2020
Portico with FlexNav TAVI late breaking data and sessions from the PCR e-Course 2020
Sponsored by Abbott
Learn about the Portico with FlexNav TAVI system and its deliverability and how it enables you to achieve favourable hemodynamics and optimal patient outcomes, while preserving coronary access.
Sponsored Session
Portico FlexNav: optimize TAVI outcomes from routine to complex cases – Live in a box
Chair: L. Sondergaard
Discussants: H. Möllmann, M. Mullen
Late-Breaking Trial
Safety outcomes for the FlexNav DS global cohort
30-day results:
- 8.3% Safety event rate
- Excellent hemodynamics: Mean gradient 7.0 mmHg and EOA 1.8 cm²
- 5.0% Major Vascular Complications
- 4.1% Moderate PVL rate, in line with real-world experience
Late-Breaking Trial
Two-year outcomes from the Portico IDE trial
- Similar clinical outcomes and hemodynamics compared with supra-annular Evolut™ R/PRO
- Superior hemodynamics compared with intra-annular SAPIEN™ 3 valve
- No difference in death or disabling stroke
- Excellent and durable valve hemodynamics: Mean gradient 8.0 mmHg and EOA 1.86 cm²
Page published on July 2020
With an unrestricted educational grant from Abbott
